Crohn's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Anssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La R

Crohn's Disease Pipeline constitutes 70+ key companies continuously working towards developing 80+ Crohn's Disease treatment therapies, analyzes DelveInsight.

Crohn's Disease Overview:

Crohn's disease (CD) is a form of inflammatory bowel disease (IBD), which involves immune-mediated inflammation of the gastrointestinal tract. In CD, the inflammation affects the entire thickness of the bowel wall, from the mucosa to the serosa. The disease follows a relapsing and remitting pattern, with repeated flare-ups causing the condition to progress from mild to moderate inflammation to more severe forms, such as fistulization (penetrating disease) or stricturing. CD can affect any part of the gastrointestinal tract, with around one-third of patients experiencing small bowel involvement, particularly the terminal ileum, 20% having only colon involvement, and about 50% having both colon and small bowel involvement. There is no cure, and most patients go through unpredictable cycles of remission and relapse, leading to a significantly reduced quality of life.

The pathophysiology of Crohn's disease is complex and involves a combination of genetic factors, infections, immune responses, environmental influences, and diet. The hallmark of the disease is transmural inflammation, which can affect the entire gastrointestinal tract from the mouth to the perianal area, though it most commonly affects the terminal ileum and right colon. The initial lesion begins as an inflammatory infiltration around an intestinal crypt, which progresses to ulceration in the superficial mucosa and eventually deeper layers. As the inflammation advances, non-caseating granulomas form in all layers of the intestinal wall. This leads to the characteristic "cobblestone" appearance of the mucosa and the presence of "skip lesions," where areas of normal tissue are interspersed with inflamed regions. Over time, as flare-ups subside, scarring replaces the inflamed areas of the intestines.

Request for a detailed insights report on Crohn's Disease pipeline insights @ https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Crohn's Disease Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Crohn's Disease Therapeutics Market.

Key Takeaways from the Crohn's Disease Pipeline Report

DelveInsight's Crohn's Disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Crohn's Disease treatment.
In October 2023, the FDA granted approval for OMVOH (mirikizumab-mrkz) infusion (300 mg/15 mL) and injection (100 mg/mL), making it the first and only interleukin-23p19 (IL-23p19) antagonist approved for treating moderately to severely active ulcerative colitis (UC) in adults.
In May 2023, the FDA also approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active Crohn's disease who have not responded adequately or are intolerant to one or more TNF blockers.
Key Crohn's Disease companies such as Anssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, and others are evaluating new drugs for Crohn's Disease to improve the treatment landscape.
Promising Crohn's Disease pipeline therapies in various stages of development include Ozanimod, Etrasimod, CBP-307, IMU-856, and others.

Crohn's Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Crohn's Disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn's Disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Crohn's Disease market.

Download our free sample page report on Crohn's Disease pipeline insights @ https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Crohn's Disease Emerging Drugs

Ozanimod: Bristol-Myers Squibb
Etrasimod: Pfizer
CBP-307: Suzhou Connect Biopharmaceuticals
IMU-856: Immunic

Crohn's Disease Companies

Over 70 key companies are working on developing therapies for Crohn's Disease. Among them, Bristol-Myers Squibb has its drug candidates for Crohn's Disease in the most advanced stage, Phase III.

DelveInsight's report covers around 200+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Crohn's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Crohn's Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Crohn's Disease Therapies and Key Companies: Crohn's Disease Clinical Trials and advancements @ https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Crohn's Disease Pipeline Therapeutic Assessment
• Crohn's Disease Assessment by Product Type
• Crohn's Disease By Stage
• Crohn's Disease Assessment by Route of Administration
• Crohn's Disease Assessment by Molecule Type

Download Crohn's Disease Sample report to know in detail about the Crohn's Disease treatment market @ Crohn's Disease Therapeutic Assessment @ https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Crohn's Disease Current Treatment Patterns
4. Crohn's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Crohn's Disease Late-Stage Products (Phase-III)
7. Crohn's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Crohn's Disease Discontinued Products
13. Crohn's Disease Product Profiles
14. Crohn's Disease Key Companies
15. Crohn's Disease Key Products
16. Dormant and Discontinued Products
17. Crohn's Disease Unmet Needs
18. Crohn's Disease Future Perspectives
19. Crohn's Disease Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Crohn's DiseaseO Pipeline Reports Offerings: https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.